Figure 3
AKT and mTOR modulate AURKA. (A) hTERT RPE-1 cells proficient or deficient for AKT were blotted for the antibodies shown. (B) Graphical representation of densitometric data shows levels of AKT and AURKA normalized to 100. Black bars—siC (scrambled controls), gray bars—siAKT. (C) Graphical representation of AURKA mRNA transcript levels in hTERT RPE-1 cells transfected with siC (black bars) and siAKT (gray bars). **Statistical significance (Students t-test) with indicated p-values. (D) hTERT RPE-1 cells transfected with myristoylated (myr) AKT and blotted as indicated. (E, G) Whole cell extracts from hTERT RPE-1 cells proficient or deficient for VHL treated with LY294002 (10 μM) (E) or MK2206 (2 μM) (G) and blotted for the antibodies shown. (F, H) Densitometric values from immunoblots were graphed to show the normalized levels of AURKA protein levels in cells treated with LY294002 (F) or MK2206 (H). **,***Statistical significance (Students t-test) with p-values as indicated. (I) Whole cell extracts from hTERT RPE-1 cells proficient or deficient for VHL treated with rapamycin (200 nM) as indicated were blotted for the antibodies shown. (J) Graphical representation of AURKA mRNA transcript levels in hTERT RPE-1 cells transfected with siC (black bars) and siVHL (gray bars) and treated with rapamycin. #Statistical significance (Students t-test) compared to siC (p < 0.05), *statistical significance (Students t-test) with indicated p-value.
